Brighton, MA, United States of America

Kwan Hui


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 28(Granted Patents)


Company Filing History:


Years Active: 1990-1994

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Kwan Hui

Introduction

Kwan Hui is a prominent inventor based in Brighton, MA, USA, recognized for his significant contributions to the field of medical research and antibody development. With two patents to his name, he has made notable strides in the innovation of synthetic peptides and their application in the detection of thrombi and fibrin deposits.

Latest Patents

Kwan's latest patents focus on synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies. The first patent details the use of peptides comprising fibrin-specific epitopic sequences to prepare hybridoma cell lines. These cell lines produce antifibrin-specific monoclonal antibodies that exhibit minimal cross-reactivity with fibrinogen, achieved through somatic cell fusion. This technology holds promise for both in vivo and in vitro detection of thrombi and fibrin deposits. The second patent reiterates this innovative method, confirming its efficacy in enhancing the accuracy of thrombus identification.

Career Highlights

Kwan Hui is associated with The General Hospital Corporation, where he has applied his expertise in protein and antibody research. His work has led to substantial advancements in biomedical diagnostics, positioning him as a valuable contributor to both his organization and the broader medical community.

Collaborations

Throughout his career, Kwan has collaborated with esteemed colleagues such as Gary R. Matsueda and Edgar Haber. These partnerships have not only fostered a rich environment for innovation but have also propelled the development of groundbreaking technologies in the biomedical field.

Conclusion

Kwan Hui exemplifies the spirit of innovation and collaboration in the realm of scientific research. His two patents underscore his commitment to advancing medical diagnostics, specifically in the detection of thrombi and fibrin deposits, paving the way for more effective clinical applications. Through his work at The General Hospital Corporation and his collaborations, Kwan continues to make a lasting impact on the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…